FrancophonIA/ELRC3.0 huggingface dataset:
English: A fourth study in 181 patients with other periodic fever syndromes found that Ilaris was more effective than placebo in achieving a response (symptoms resolved with no new flare ups).
Estonian: Neljas uuring, milles osales 181 muude perioodilise palaviku sündroomidega patsienti, tõendas, et Ilaris on ravivastuse tekkimisel efektiivsem kui platseebo (sümptomid kadusid ägenemiseta).
English: For more information about treatment with Ilaris, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ilarisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: A study in 84 patients with childhood Still's disease (also known as systemic juvenile idiopathic arthritis, SJIA) found that Ilaris was more effective than placebo at reducing symptoms of arthritis: around 84% of patients who received Ilaris achieved the required reduction in symptoms, compared with about 10% of patients who received placebo.
Estonian: Uuring, milles osales 84 lapseea Stilli tõvega (süsteemne lapseea idiopaatiline artriit) patsienti, tõendas, et Ilaris on artriidi sümptomite vähendamisel efektiivsem kui platseebo: sümptomid vähenesid nõuetekohaselt ligikaudu 84% Ilarist manustanud patsientidest ja ligikaudu 10% platseebot manustanud patsientidest.
English: − tumour necrosis factor receptor associated periodic syndrome (TRAPS);
Estonian: − kasvaja nekroositeguri retseptoriga seotud perioodiline sündroom (TRAPS);
English: In the two other CAPS studies, which did not compare Ilaris with any other treatment, 85% of patients on Ilaris had no relapses at all.
Estonian: Kahes ülejäänud krüopüriiniga seotud perioodiliste sündroomide uuringus, milles ei võrreldud Ilarist muude raviviisidega, ei esinenud relapse 85%-l Ilarist manustanud patsientidest.
English: This messenger is involved in causing inflammation and is found in high levels in patients with periodic fever syndromes, Still's disease and gouty arthritis.
Estonian: See virgatsaine osaleb põletiku tekitamises ja selle sisaldus on perioodilise palaviku sündroomidega, Stilli tõvega ja podagraartriidiga patsientidel suur.
English: • Still's disease, a rare disease causing inflammation of joints as well as rash and fever (in adults and children aged 2 and above);
Estonian: • Stilli tõbi (haruldane haigus, mis põhjustab liigeste põletikku, löövet ja palavikku täiskasvanutel ja vähemalt 2-aastastel lastel);
English: Ilaris is given as a single injection under the skin every 8 weeks for CAPs and every 4 weeks for the other periodic fever syndromes (TRAPS, HIDS/MKD and FMF) and Still's disease.
Estonian: Ilarist manustatakse krüopüriiniga seotud perioodiliste sündroomide korral ühekordse nahaaluse süstena iga 8 nädala järel ning muude perioodilise palaviku sündroomide (kasvaja nekroositeguri retseptoriga seotud perioodiline sündroom, hüperimmunoglobuliin-D-sündroom, mevalonaadi kinaasi vaegus ja perekondlik Vahemere palavik) ja Stilli tõve korral iga 4 nädala järel.
English: Ilaris can only be obtained with a prescription.
Estonian: Ilaris on retseptiravim.
English: • Gouty arthritis, painful inflammation of the joints caused by deposit of urate crystals (in adults).
Estonian: • podagraartriit (uraadikristallide ladestumisest põhjustatud valulik liigesepõletik täiskasvanutel).
English: In one of the studies, none of the patients with CAPS who received Ilaris during the 24-week treatment period had a relapse, compared with 81% of patients who received placebo (a dummy treatment).
Estonian: Ühes uuringus ei esinenud relapse ühelgi krüopüriiniga seotud perioodiliste sündroomidega patsiendil, kes said 24-nädalase raviperioodi jooksul Ilarist; platseebot (näiv ravim) saanud patsientide sama näitaja oli 81%.
English: For information on doses and dose adjustments, see the summary of product characteristics (also part of the EPAR).
Estonian: Annuste ja nende kohandamise üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: Still's disease
Estonian: Stilli tõbi
English: Ilaris contains the active substance canakinumab.
Estonian: Ilaris sisaldab toimeainena kanakinumaabi.
English: In patients with gouty arthritis, a single injection is given on-demand to treat gouty arthritis attacks.
Estonian: Podagraartriidiga patsientidele tehakse podagraartriidi episoodi korral vajaduspõhine ühekordne süst.
English: Ilaris canakinumab
Estonian: Ilaris kanakinumaab
English: Doctors and patients must be aware of this possibility.
Estonian: Arstid ja patsiendid peavad seda riski teadma.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Bemfola on 27 March 2014.
Estonian: Euroopa Komisjon andis müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. märts 2014.
English: A risk management plan has been developed to ensure that Bemfola is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Bemfola võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Bemfola?
Estonian: Mis meetmed võetakse, et tagada Bemfola ohutu ja efektiivne kasutamine?
English: The full EPAR and risk management plan summary for Bemfola can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Bemfola kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Bemfola
Estonian: Muu teave Bemfola kohta
English: What is Bemfola and what is it used for?
Estonian: Mis on Bemfola ja milleks seda kasutatakse?
English: What are the risks associated with Bemfola?
Estonian: Mis riskid Bemfolaga kaasnevad?
English: Why is Bemfola approved?
Estonian: Miks Bemfola heaks kiideti?
English: The most common side effects with Bemfola (which may affect more than 1 in 10 people) are reactions at the injection site (pain, redness, bruising, swelling or irritation).
Estonian: Bemfola kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on süstekoha reaktsioon (valu, punetus, verevalum, turse või ärritus).
English: The main measure of effectiveness was the number of eggs collected.
Estonian: Ravimi efektiivsuse põhinäitaja oli eraldunud munarakkude arv.
English: It is not intended to provide practical advice on how to use Bemfola.
Estonian: Hindamisaruandes ei anta Bemfola kasutamise praktilisi nõuandeid.
English: • men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Estonian: • Mehed, kellel on hüpogonadotroopne hüpogonadism (hormoonpuudulikkusest tingitud haruldane haigus).
English: The dose of Bemfola and how often it is given depend on why it is being used and on the patient's response to treatment.
Estonian: Bemfola annus ja manustamissagedus sõltuvad sellest, milleks ravimit kasutatakse, ja patsiendi ravivastusest.
English: This means that Bemfola is similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Estonian: See tähendab, et Bemfola sarnaneb bioloogilise ravimiga (võrdlusravim), millel juba on Euroopa Liidus müügiluba.
English: It is used to treat the following groups:
Estonian: Seda kasutatakse järgmistel patsiendirühmadel.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Bemfola has been shown to have a comparable quality, safety and effectiveness to GONAL-f.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Bemfola võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi GONAL-f profiiliga.
English: In women, ovarian cysts (sacs of fluid within the ovaries) and headache are also seen in more than 1 patient in 10.
Estonian: Naistel on esinenud munasarjatsüstid (vedelikukogumid munasarjas) ja peavalu enam kui 1 patsiendil 10st.
English: It must not be used when it would not be possible for the patient to have an effective response, such as in patients whose ovaries or testicles do not work or in women who should not get pregnant for medical reasons.
Estonian: Seda ei tohi kasutada ka juhul, kui patsiendil ei saa tekkida ravivastust, näiteks kui munasarjad või munandid ei toimi või kui rasestuda ei tohi meditsiinilistel põhjustel.
English: The Committee recommended that Bemfola be given marketing authorisation.
Estonian: Komitee soovitas anda Bemfola müügiloa.
English: Bemfola was compared with GONAL-f in one main study involving 372 women who were undergoing assisted reproductive techniques.
Estonian: Bemfolat võrreldi ravimiga GONAL-f ühes põhiuuringus, kus osales 372 viljatusravi saavat naist.
English: The medicine can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of fertility problems
Estonian: Bemfola on retseptiravim ja ravi peab alustama ainult viljakusprobleemide ravis kogenud arsti järelevalve all.
English: Bemfola follitropin alfa
Estonian: Bemfola alfafollitropiin
English: The follitropin alfa in Bemfola, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology': it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce human FSH.
Estonian: Bemfolas (nagu ka võrdlusravimis GONAL-f) sisalduvat alfafollitropiini valmistatakse rekombinant-DNA tehnika abil: seda toodavad rakud, millesse on viidud inimese FSH teket võimaldav geen (DNA).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bemfola, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Bemfola omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In the body, FSH controls reproductive function: in women, it stimulates the production of eggs in the ovaries; in men, it stimulates the production of sperm in the testicles.
Estonian: Organismis reguleerib FSH reproduktiivfunktsiooni: naistel stimuleerib FSH munasarjades munarakkude eraldumist ja meestel munandites seemnerakkude teket.
English: This is a summary of the European public assessment report (EPAR) for Bemfola.
Estonian: See on ravimi Bemfola Euroopa avaliku hindamisaruande kokkuvõte.
English: Bemfola is a medicine that contains the active substance follitropin alfa.
Estonian: Bemfola on ravim, mis sisaldab toimeainena alfafollitropiini.
English: The study showed that Bemfola was as effective as GONAL-f at stimulating the ovaries during assisted reproductive techniques, as an average of 11 eggs were retrieved with both medicines.
Estonian: Uuringus oli Bemfola munasarjadest munarakkude eraldumise stimuleerimisel viljatusravi ajal sama efektiivne kui GONAL-f: mõlema ravimiga eraldus keskmiselt 11 munarakku.
English: For more information about treatment with Bemfola, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Bemfolaga toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Bemfola has been shown to be comparable to the reference medicine, GONAL-f.
Estonian: Uuringus tõestati Bemfola võrreldavus võrdlusravimiga GONAL-f.
English: Bemfola is given by injection under the skin once a day.
Estonian: Bemfolat manustatakse nahaaluse süstina üks kord ööpäevas.
English: For practical information about using Bemfola, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Bemfola kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Bemfola must not be used in people who are hypersensitive (allergic) to follitropin alfa, FSH, or any of the other ingredients.
Estonian: Bemfolat ei tohi kasutada patsiendid, kes võivad olla alfafollitropiini, FSH või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It must not be used in patients with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on hüpofüüsi (ajuripatsi) või hüpotalamuse kasvaja või rinna-, emaka- või munasarjavähk.
English: Therefore, the CHMP's view was that, as for GONAL-f, the benefits of Bemfola outweigh the identified risks.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka võrdlusravimi GONAL-f korral, ületab ravimi Bemfola kasulikkus sellega kaasnevad riskid.
English: How is Bemfola used?
Estonian: Kuidas Bemfolat kasutatakse?
English: What benefits of Bemfola have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Bemfola kasulikkus?
English: In women, Bemfola must not be used when there is enlargement of an ovary or a cyst that is caused by something other than polycystic ovarian disease, or when there is unexplained bleeding from the vagina.
Estonian: Naised ei tohi Bemfolat kasutada laienenud munasarjade või sellise tsüsti korral, mis ei ole tingitud munasarjade polütsüstilisest haigusest, ega tupeverejooksu korral.
English: • women who do not produce eggs and who do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs);
Estonian: • Naised, kellel ei eraldu munarakke ja kelle ravi klomifeentsitraadiga (samuti ovulatsiooni stimuleeriv ravim) ei ole andnud tulemusi
English: The reference medicine for Bemfola is GONAL-f. For more information on biosimilar medicines, see the question-and-answer document here.
Estonian: Bemfola võrdlusravim on GONAL-f. Bioloogiliselt sarnase ravimite lisateave on teabedokumendis siin.
English: • women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH).
Estonian: • Naised, kelle organismis tekib luteiniseerivat hormooni (lutropiini, LH) ja folliikuleid stimuleerivat hormooni (FSH) väga vähe.
English: For the full list of all side effects reported with Bemfola, see the package leaflet.
Estonian: Bemfola kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Bemfola is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries;
Estonian: Bemfolat kasutatakse koos luteiniseerivat hormooni sisaldava ravimiga, et stimuleerida munarakkude küpsemist munasarjades.
English: In some women, the ovaries can over-respond to stimulation.
Estonian: Mõnikord võivad munasarjad reageerida stimulatsioonile liiga tugevasti (munasarja hüperstimulatsiooni sündroom).
English: Bemfola is a ‘biosimilar medicine'.
Estonian: Bemfola on bioloogiliselt sarnane ravim.
English: Bemfola is given to stimulate the ovaries to produce more than one egg at a time;
Estonian: Bemfolat manustatakse munasarjade stimuleerimiseks, et nendest vabaneks korraga mitu munarakku.
English: Bemfola is used together with human chorionic gonadotrophin (hCG) therapy to stimulate sperm production.
Estonian: Bemfolat kasutatakse seemnerakkude tekke stimuleerimiseks koos inimese kooriongonadotropiiniga (hCG).
English: • women who are undergoing assisted reproductive techniques (fertility treatment) such as in vitro fertilisation.
Estonian: • Viljatusravi saavad naised (tehisviljastamine, näiteks katseklaasiviljastamine).
English: The active substance in Bemfola, follitropin alfa, is a copy of the natural hormone FSH.
Estonian: Bemfola toimeaine alfafollitropiin on loodusliku folliikuleid stimuleeriva hormooni (FHS) tehisvariant.
English: How does Bemfola work?
Estonian: Kuidas Bemfola toimib?
English: Bemfola is available as a solution for injection in a prefilled pen.
Estonian: Bemfola on eeltäidetud pensüstlas turustatav süstelahus.
English: It is available as ‘orodispersible' tablets (5, 10, 15 and 20 mg).
Estonian: Seda turustatakse suus dispergeeruvate tablettidena (5, 10, 15 ja 20 mg).
English: The full EPAR for Zyprexa Velotab can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zyprexa Velotabi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zyprexa Velotab on 3 February 2000.
Estonian: Euroopa Komisjon andis Zyprexa Velotabi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. veebruaril 2000.
English: The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Estonian: Suus lahustuvad tabletid asetatakse keelele, kus need süljes kiiresti lagunevad, või segatakse enne neelamist veega.
English: Three studies were also carried to show that, when taken by mouth, the two medicines produce equivalent levels of olanzapine in the blood.
Estonian: Tehti kolm lisauuringut, et näidata, et suukaudsel manustamisel saavutatakse kummagi ravimiga olansapiini ühesugune sisaldus veres.
English: The recommended starting dose of Zyprexa Velotab depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Estonian: Zyprexa Velotabi tablettide soovituslik algannus sõltub ravitavast haigusest: skisofreenia korral ja maaniaepisoodide ennetamiseks kasutatakse annust 10 mg ööpäevas ning maaniaepisoodide raviks 15 mg ööpäevas, välja arvatud kasutamisel koos teiste ravimitega, mil algannus võib olla 10 mg ööpäevas.
English: Zyprexa Velotab olanzapine
Estonian: Zyprexa Velotab olansapiin
English: The most common side effects with Zyprexa Velotab (seen in more than 1 patient in 10) are somnolence (sleepiness), weight gain, orthostatic hypotension (sudden drop in blood pressure on standing up) and raised levels of prolactin (a hormone).
Estonian: Zyprexa Velotabi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on unisus, kehakaalu tõus, ortostaatiline hüpotensioon (madal vererõhk seismisel) ja prolaktiini (teatud hormooni) taseme tõus.
English: For more information about treatment with Zyprexa Velotab, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Zyprexa Velotabiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zyprexa Velotab.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Zyprexa Velotab must not be used in people who are hypersensitive (allergic) to olanzapine or any of the other ingredients.
Estonian: Zyprexa Velotabi ei tohi kasutada patsiendid, kes on olansapiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Zyprexa Velotab contains the same active substance as another medicine called Zyprexa that has been authorised in the European Union (EU) since 1996.
Estonian: Zyprexa Velotab sisaldab sama toimeainet kui Zyprexa, millel on Euroopa Liidus müügiluba juba 1996. aastast.
English: The CHMP decided that Zyprexa Velotab's benefits are greater than its risks and recommended that Zyprexa Velotab be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zyprexa Velotabi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Because of this, the studies done with Zyprexa were used to support the use of Zyprexa Velotab.
Estonian: Sellel põhjusel kasutatakse Zyprexa Velotabi kasutamise toetuseks Zyprexaga tehtud uuringuid.
English: Other information about Zyprexa Velotab
Estonian: Muu teave Zyprexa Velotabi kohta
English: Zyprexa Velotab is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Estonian: Zyprexa Velotabi saab kasutada ka esialgse ravivastusega patsientide paranemistulemuse efektiivseks säilitamiseks.
English: Zyprexa Velotab is used to treat adults with schizophrenia.
Estonian: Zyprexa Velotabi kasutatakse skisofreenia ravimiseks täiskasvanud patsientidel.
English: Zyprexa Velotab was as effective as the medicines that it was compared with for the treatment of adults with schizophrenia, the treatment of moderate to severe manic episodes in adults, and the prevention of recurrence in adults with bipolar disorder.
Estonian: Zyprexa Velotab oli skisofreenia ravimisel, mõõdukate ja raskete maaniaepisoodide ravimisel ning taastekke ennetamisel bipolaarse meeleoluhäirega täiskasvanud patsientidel sama efektiivne kui võrdlusravimid.
English: For the full list of all side effects reported with Zyprexa Velotab, see the package leaflet.
Estonian: Zyprexa Velotabi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Zyprexa Velotab is a medicine that contains the active substance olanzapine.
Estonian: Zyprexa Velotab on ravim, mis sisaldab toimeainena olansapiini.
English: Like Zyprexa, Zyprexa Velotab was more effective at improving symptoms than placebo (a dummy treatment).
Estonian: Nagu Zyprexa, leevendas Zyprexa Velotab sümptomeid platseebost (näiv ravim) efektiivsemini.
English: The active substance in Zyprexa Velotab, olanzapine, is an antipsychotic medicine.
Estonian: Zyprexa Velotabi toimeaine olansapiin on antipsühhootikum (psühhoosivastane ravim).
English: What is the risk associated with Zyprexa Velotab?
Estonian: Mis riskid Zyprexa Velotabiga kaasnevad?
English: Zyprexa Velotab is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Estonian: Samuti kasutatakse Zyprexa Velotabi mõõdukate või raskete maaniaepisoodide (meeleolu äärmuslik tõus) raviks täiskasvanud patsientidel.
English: How has Zyprexa Velotab been studied?
Estonian: Kuidas Zyprexa Velotabi uuriti?
English: This is a summary of the European public assessment report (EPAR) for Zyprexa Velotab.
Estonian: See on ravimi Zyprexa Velotab Euroopa avaliku hindamisaruande kokkuvõte.
English: What is Zyprexa Velotab used for?
Estonian: Milleks Zyprexa Velotabi kasutatakse?
English: Why has Zyprexa Velotab been approved?
Estonian: Miks Zyprexa Velotab heaks kiideti?
English: How is Zyprexa Velotab used?
Estonian: Kuidas Zyprexa Velotabi kasutatakse?
English: How does Zyprexa Velotab work?
Estonian: Kuidas Zyprexa Velotab toimib?
English: What benefit has Zyprexa Velotab shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zyprexa Velotabi kasulikkus?
English: What is Zyprexa Velotab?
Estonian: Mis on Zyprexa Velotab?
English: However, all other concerns remain.
Estonian: Kuid teised probleemid jäid püsima.
English: There was also insufficient evidence of maintenance of the medicine's effects.
Estonian: Ravimi toime säilimise kohta ei olnud samuti piisavalt tõendeid.
English: International non-proprietary name (INN): natalizumab
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): natalisumab
English: The balance of benefits and risks for TYSABRI remains unchanged.
Estonian: TYSABRI kasulikkuse ja riskide suhe jääb samaks.
English: The main measure of effectiveness was the proportion of patients whose symptoms improved after 10 weeks.
Estonian: Efektiivsust mõõdeti põhiliselt nende patsientide osakaaluga, kelle sümptomid olid 10 nädalaga leevendunud.
English: The company that applied for authorisation is Elan Pharma International Ltd.
Estonian: Müügiluba taotles ettevõte Elan Pharma International Ltd.